From Barchart: 2025-04-18 05:16:00

Bausch + Lomb’s stock price has dropped 41.5% over the last six months to $12.06 per share, raising questions for investors about its potential. The company has a long history in eye health innovation, but three key factors suggest caution: slow long-term revenue growth at 5% annually, declining EPS by 23.5% yearly, and a short cash runway with $4.78 billion in debt exceeding $316 million in cash. Unless there are significant changes, Bausch + Lomb may need to raise capital, hindering shareholder returns. With a forward P/E ratio of 15.7, there may be better investment opportunities available.

As the market faces uncertainty in 2025, focus on companies with strong performance regardless of economic or political changes. Consider exploring the Top 9 Market-Beating Stocks list, featuring high-quality stocks that have delivered a 175% return in the last five years. Successful companies like Nvidia and Comfort Systems have been highlighted in the past, offering potential for significant growth. Explore potential winners with StockStory’s curated list for free today.



Read more at Barchart: 3 Reasons to Sell BLCO and 1 Stock to Buy Instead